cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biomarkers
The ratio of VEGF-A to its soluble receptor changes in breast cancer patients
December 14th, 2004
The ratio of VEGF-A to its soluble receptor changes in breast cancer patients. "As circulating levels of vascular endothelial growth factor (VEGF-A) are raised in malignancy, the aim of this study was to investigate whether similar changes occur in two related factors, VEGF-D and the soluble VEGF-A receptor Flt-1 (sFlt-1). Circulating levels of VEGF-A, VEGF-D and sFlt-1 were determined by enzyme-linked immunosorbent assay (ELISA) in 51 patients with primary breast cancer and matched healthy controls. Results were correlated with clinicopathological data," investigators in England report. "Whilst there was a difference in VEGF-A levels between patient...
Source: cancer weekly (2004-12-14)
|
